HOME >> MEDICINE >> NEWS
Gene mutations predict which lung cancers will respond to Iressa

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have discovered a molecular marker that identifies lung cancer patients whose tumors will respond to treatment with the drug Iressa (gefitinib). Their findings, which will be published in the May 20 New England Journal of Medicine, are being released online today to coincide with the online release by Science of related research from Dana-Farber Cancer Institute.

"This discovery will help us significantly improve the treatment of many lung cancer patients and is also an important next step in the molecular targeting of cancer drugs," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the NEJM paper. "We're hopeful that what we have learned will eventually lead to more new drugs that will target tumor-specific mutations without affecting normal tissues."

Iressa was approved a year ago for the treatment of advanced non-small-cell lung cancer (NSCLC), a tumor that is particularly difficult to treat and is the leading cause of cancer deaths in the U.S. In a major clinical trial Iressa caused tumors to shrink significantly in only 13.6 percent of patients, but some of those responses were rapid and dramatic. As a result, the FDA approved the drug because there are no other treatment options for NSCLC patients for whom standard chemotherapy has failed.

Iressa acts by disabling the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, halting a sequence of signals that can lead to the uncontrolled growth characterizing a malignant tumor. In their search for an answer to why the drug worked so well for some NSCLC patients but was of no assistance to others, the MGH team screened tumor samples from MGH patients who participated in the Iressa clinical trial to search for mutations in the EGFR gene.

Initial analysis found mutations affecting the same area (the ATP cleft of the kinase domain) of the receptor prot
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
29-Apr-2004


Page: 1 2 3

Related medicine news :

1. Non-invasive and invasive breast cancers share the same genetic mutations
2. Both inherited traits and tumor mutations affect response to treatment of leukemia
3. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
4. Gene mutations responsible for childhood cataracts discovered
5. Breast cancer patients with BRCA1 or 2 mutations twice as likely to have double mastectomy
6. Breast cancer patients with BRCA 1/2 mutations twice as likely to choose double mastectomy
7. Mayo Clinic researchers discover gene mutations that ignore stress, lead to heart failure
8. In 15 seconds, new test will ID presence of 25 most common mutations of cystic fibrosis
9. Northwestern on trail of gene mutations that trigger sex reversal
10. Gene mutations found that lead to prostate cancer in mice new mouse model developed to study the disease
11. New evaluation tool reliably predicts recovery from coma

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene mutations predict which lung cancers will respond Iressa

(Date:8/31/2015)... ... , ... On Saturday, July 11, 2015, during the annual New York State ... was proud to recognize Dr. Merritt F. Spear as the 2015 recipient of the ... long-time NYSATA member and Ithaca College athletic trainer and educator, is considered for individuals ...
(Date:8/31/2015)... ... ... Adult & Pediatric Dermatology in Greenwood Village, CO has launched a new ... services available to help them. , The website better showcases the practice to ... to view the website seamlessly on any desktop computer, tablet or mobile device. , ...
(Date:8/31/2015)... ... ... The Marietta dentists and staff at Verde Pointe Dental Associates ... staff ran a 5K race, the Iron Horse for Enduring Hearts on August 30th, ... the event to help support projects with funding to increase understanding of clinical and ...
(Date:8/30/2015)... ... 31, 2015 , ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging ... http://www.fdanews.com/importholdcrisis , US authorities are holding imports more than ever before, particularly ... With alerts on an uptick and a new final rule, having a top-notch import ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... across platforms and devices, today announced it is a Silver Sponsor of the ... at Sky City Convention Centre in Auckland, NZ. Throughout the event, AvePoint will ...
Breaking Medicine News(10 mins):Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 2Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 3Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... Seroquel) is an important drug for the treatment ... in 2000, quetiapine was listed in the Catalogue ...
(Date:8/28/2015)... N.J. , Aug. 28, 2015  IP Shakti, LLC, ... LLC. ... "Our new corporate identity signifies our transformation ... world,s first predictive analytics platform for patent claim validity." ... the launch of the proprietary AIA Shield™ platform, the Company ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
Cached News: